SuperworthBiotech stocks with the lowest PE ratio
Share price divided by earnings per share over the last twelve months. As of .
- Ranked
- 16
- of 146 biotech stocks we cover
- Median
- 25.8×
- Lowest
- 11.1×
- PLX
- Range
- 11.1× to 242×
median 25.8×
11.1×242×
| # | Company | PE | PE vs its 10 years | Revenue growth (TTM) | Market cap |
|---|---|---|---|---|---|
| 1 | PLXProtalix BioTherapeutics | 11.1× | 8th pct | +30.1% | $205.5M |
| 2 | MGTXMeiraGTx | 13.0× | n/a | n/m | $884.6M |
| 3 | INCYIncyte | 14.7× | 4th pct | +26.9% | $23.5B |
| 4 | ADMAAdma Biologics | 15.3× | 20th pct | +8.0% | $2.4B |
| 5 | REGNRegeneron Pharmaceuticals | 19.9× | 52nd pct | +9.3% | $82.9B |
| 6 | EXELExelixis | 20.3× | 42nd pct | +9.2% | $16B |
| 7 | NBIXNeurocrine Biosciences | 20.9× | 5th pct | +34.4% | $14.5B |
| 8 | UTHRUnited Therapeutics | 21.0× | 99th pct | +2.5% | $25.2B |
| 9 | VRTXVertex Pharmaceuticals | 30.5× | 61st pct | +10.2% | $132.8B |
| 10 | HALOHalozyme Therapeutics | 37.5× | 88th pct | +41.2% | $14.3B |
| 11 | ALNYAlnylam Pharmaceuticals | 37.8× | n/a | +95.1% | $30B |
| 12 | KRYSKrystal Biotech | 39.0× | 33rd pct | +22.6% | $9.2B |
| 13 | TECHBIO-TECHNE | 63.1× | 53rd pct | −0.4% | $11.4B |
| 14 | ONCBeOne Medicines | 67.6× | n/a | +34.3% | $42.9B |
| 15 | VCELVericel | 92.5× | 16th pct | +23.0% | $2.2B |
| 16 | RGENRepligen | 242× | 89th pct | +16.5% | $10B |
Not ranked: 104 with a loss over the last year, 5 with not a meaningful number, 2 with a quarter missing. 19 companies whose data behind this number has a caveat are left out until it is checked.
A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.